Blood unconjugated bilirubin and tacrolimus are negative predictors of specific cellular immunity in kidney transplant recipients after SAR-CoV-2 inactivated vaccination

© 2023. The Author(s)..

The immunogenicity of SARS-CoV-2 vaccines is poor in kidney transplant recipients (KTRs). The factors related to poor immunogenicity to vaccination in KTRs are not well defined. Here, observational study demonstrated no severe adverse effects were observed in KTRs and healthy participants (HPs) after first or second dose of SARS-CoV-2 inactivated vaccine. Different from HPs with excellent immunity against SARS-CoV-2, IgG antibodies against S1 subunit of spike protein, receptor-binding domain, and nucleocapsid protein were not effectively induced in a majority of KTRs after the second dose of inactivated vaccine. Specific T cell immunity response was detectable in 40% KTRs after the second dose of inactivated vaccine. KTRs who developed specific T cell immunity were more likely to be female, and have lower levels of total bilirubin, unconjugated bilirubin, and blood tacrolimus concentrations. Multivariate logistic regression analysis found that blood unconjugated bilirubin and tacrolimus concentration were significantly negatively associated with SARS-CoV-2 specific T cell immunity response in KTRs. Altogether, these data suggest compared to humoral immunity, SARS-CoV-2 specific T cell immunity response are more likely to be induced in KTRs after administration of inactivated vaccine. Reduction of unconjugated bilirubin and tacrolimus concentration might benefit specific cellular immunity response in KTRs following vaccination.

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:13

Enthalten in:

Scientific reports - 13(2023), 1 vom: 04. Mai, Seite 7263

Sprache:

Englisch

Beteiligte Personen:

Zhang, Lei [VerfasserIn]
Yang, Jiaqing [VerfasserIn]
Deng, Min [VerfasserIn]
Xu, Chuanhui [VerfasserIn]
Lai, Changchun [VerfasserIn]
Deng, Xuanying [VerfasserIn]
Wang, Yan [VerfasserIn]
Zhou, Qiang [VerfasserIn]
Liu, Yichu [VerfasserIn]
Wan, Li [VerfasserIn]
Li, Pingchao [VerfasserIn]
Fang, Jiali [VerfasserIn]
Hou, Jingcai [VerfasserIn]
Lai, Xingqiang [VerfasserIn]
Ma, Feifei [VerfasserIn]
Li, Ning [VerfasserIn]
Li, Guanghui [VerfasserIn]
Kong, Weiya [VerfasserIn]
Zhang, Weiting [VerfasserIn]
Li, Jiali [VerfasserIn]
Cao, Mibu [VerfasserIn]
Feng, Liqiang [VerfasserIn]
Chen, Zheng [VerfasserIn]
Chen, Ling [VerfasserIn]
Ji, Tianxing [VerfasserIn]

Links:

Volltext

Themen:

Antibodies, Viral
Bilirubin
COVID-19 Vaccines
Journal Article
Observational Study
RFM9X3LJ49
Research Support, Non-U.S. Gov't
Tacrolimus
WM0HAQ4WNM

Anmerkungen:

Date Completed 08.05.2023

Date Revised 11.05.2023

published: Electronic

Citation Status MEDLINE

doi:

10.1038/s41598-023-29669-8

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM356459764